AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Intro
This chapter explores the FDA's recent approval of Cabenphi, an antipsychotic with a unique mechanism that moves beyond traditional dopamine antagonists. It also recounts personal experiences during a tumultuous conference impacted by Hurricane Helene, while delving into the scientific background of its key component, xanomaline.